Supernus price target raised to $40 from $36 at Piper Sandler

Piper Sandler raised the firm’s price target on Supernus (SUPN) to $40 from $36 and keeps a Neutral rating on the shares. Though the firm does wonder if there is more room for multiple expansion given the company’s longer-term LOE exposure, Piper does concede that Onapgo, an infusion pump that provides continuous subcutaneous delivery of apomorphine for patients with advanced Parkinson’s disease, is off to a strong start and bears watching as an upside driver.